Compare HCAT & CNTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | CNTN |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.4M | 146.5M |
| IPO Year | 2019 | 2021 |
| Metric | HCAT | CNTN |
|---|---|---|
| Price | $1.85 | $2.02 |
| Analyst Decision | Hold | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $2.53 | N/A |
| AVG Volume (30 Days) | ★ 856.8K | 689.9K |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.10 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $311,136,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.48 | N/A |
| 52 Week Low | $0.96 | $1.75 |
| 52 Week High | $3.79 | $5.27 |
| Indicator | HCAT | CNTN |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 45.87 |
| Support Level | $1.61 | $1.75 |
| Resistance Level | $2.37 | $3.80 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 26.35 | 78.38 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platform, analytics applications and support services and generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company operates in two reportable segments: digital asset treasury and clinical stage bio-technology. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.